Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Darbepoetin Alfa Treatment of Anemia in Hemodialysis Subjects
Phase 3
Completed
- Conditions
- Anemia
- First Posted Date
- 2005-07-14
- Last Posted Date
- 2007-12-28
- Lead Sponsor
- Amgen
- Registration Number
- NCT00119587
A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy
Phase 3
Completed
- Conditions
- AnemiaNon-Myeloid Malignancies
- Interventions
- First Posted Date
- 2005-07-12
- Last Posted Date
- 2013-04-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 705
- Registration Number
- NCT00118638
Treatment for Subjects With Non-Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- Non-Hodgkin's Lymphoma
- First Posted Date
- 2005-07-11
- Last Posted Date
- 2009-07-20
- Lead Sponsor
- Amgen
- Registration Number
- NCT00117897
Treatment for Elderly Patients With High Risk Breast Cancer
Phase 3
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2005-07-11
- Last Posted Date
- 2008-05-16
- Lead Sponsor
- Amgen
- Registration Number
- NCT00117910
A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- Non-Hodgkin's Lymphoma
- First Posted Date
- 2005-07-07
- Last Posted Date
- 2008-05-16
- Lead Sponsor
- Amgen
- Registration Number
- NCT00117455
A Study of Carboplatin/Paclitaxel With Pegfilgrastim Supported by Haematopoietic Progenitor Cell Re-Infusion in Whole Blood
Phase 2
Completed
- Conditions
- Lung CancerOvarian CancerBreast Cancer
- Interventions
- First Posted Date
- 2005-07-07
- Last Posted Date
- 2013-05-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 61
- Registration Number
- NCT00117442
Impact of Darbepoetin Alfa on Exercise Tolerance and Left Ventricular Structure in Subjects With Symptomatic Congestive Heart Failure (CHF) and Anemia
Not Applicable
Completed
- Conditions
- Congestive Heart FailureAnemia
- First Posted Date
- 2005-07-06
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- Amgen
- Registration Number
- NCT00117234
A Study of Repeat-Dose Subcutaneous Darbepoetin Alfa in Subjects With Congestive Heart Failure and Anemia, and a Single Dose in Healthy Age- and Sex-Matched Control Subjects
Phase 1
Completed
- Conditions
- AnemiaCongestive Heart Failure
- First Posted Date
- 2005-07-06
- Last Posted Date
- 2009-10-16
- Lead Sponsor
- Amgen
- Registration Number
- NCT00117247
Study to Evaluate Effectiveness of Aranesp®
Phase 4
Completed
- Conditions
- Kidney Disease
- First Posted Date
- 2005-07-04
- Last Posted Date
- 2011-01-21
- Lead Sponsor
- Amgen
- Registration Number
- NCT00117130
A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®
Phase 4
Completed
- Conditions
- Anemia
- First Posted Date
- 2005-07-04
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 2423
- Registration Number
- NCT00117117
© Copyright 2025. All Rights Reserved by MedPath